Business
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
New York, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, announces its role as exclusive placement agent in a $4.3 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT). Lixte Biotechnology Holdings, Inc., a clinical stage pharmaceutical company focused on advancing cancer treatments, entered into definitive agreements with accredited investors for the purchase and sale of shares of Common Stock and pre
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"image","alt":"Spartan Capital Securities, LLC","displaySize":"","headline":null,"caption":"Spartan Capital Securities, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/3782396156a864df4205f88bae0b17cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cAuJsOyL2Wz202dUc1iJwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3782396156a864df4205f88bae0b17cc","width":300,"height":98}},"lazy":false},{"type":"text","content":"New York, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, announces its role as exclusive placement agent in a $4.3 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT).","length":263,"tagName":"p"},{"type":"text","content":"Lixte Biotechnology Holdings, Inc., a clinical stage pharmaceutical company focused on advancing cancer treatments, entered into definitive agreements with accredited investors for the purchase and sale of shares of Common Stock and pre funded and investor warrants. The entire transaction has been priced at the market under Nasdaq rules.","length":339,"tagName":"p"},{"type":"text","content":"The offering consisted of 1,051,342 Common Units or Pre Funded Units. Each Common Unit included one share of Common Stock and one Common Warrant to purchase one share of Common Stock at an exercise price of $3.96. Each Pre Funded Unit included one Pre Funded Warrant with an exercise price of $0.00001 and one Common Warrant. The public offering price per Common Unit was $4.09 and $4.08999 per Pre Funded Unit. The Common Warrants are immediately exercisable and expire sixty months from issuance.","length":498,"tagName":"p"},{"type":"text","content":"Aggregate gross proceeds to the Company are expected to be approximately $4.3 million. Net proceeds, together with existing cash, are expected to support general corporate purposes and working capital.","length":201,"tagName":"p"},{"type":"text","content":"“This transaction highlights our continued commitment to supporting innovative life sciences companies through tailored capital solutions,” said John Lowry, CEO of Spartan Capital Securities. “Lixte continues to advance a compelling clinical program in oncology, and we appreciate the opportun...